As of 2025-11-04, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -12.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,307.80 mil USD. TXG's TTM EBITDA according to its financial statements is -101.17 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 16.5x | 14.7x |
| Forward P/E multiples | 19.2x - 21.3x | 20.0x |
| Fair Price | (12.41) - (10.23) | (10.92) |
| Upside | -190.6% - -174.7% | -179.7% |
| Date | EV/EBITDA |
| 2025-11-03 | -12.93 |
| 2025-10-31 | -12.85 |
| 2025-10-30 | -11.38 |
| 2025-10-29 | -11.94 |
| 2025-10-28 | -12.48 |
| 2025-10-27 | -12.79 |
| 2025-10-24 | -13.01 |
| 2025-10-23 | -12.51 |
| 2025-10-22 | -11.16 |
| 2025-10-21 | -12.10 |
| 2025-10-20 | -12.24 |
| 2025-10-17 | -10.63 |
| 2025-10-16 | -11.30 |
| 2025-10-15 | -10.70 |
| 2025-10-14 | -10.27 |
| 2025-10-13 | -10.34 |
| 2025-10-10 | -10.18 |
| 2025-10-09 | -10.48 |
| 2025-10-08 | -10.92 |
| 2025-10-07 | -10.34 |
| 2025-10-06 | -11.62 |
| 2025-10-03 | -11.76 |
| 2025-10-02 | -11.22 |
| 2025-10-01 | -11.32 |
| 2025-09-30 | -10.45 |
| 2025-09-29 | -10.02 |
| 2025-09-26 | -10.49 |
| 2025-09-25 | -10.77 |
| 2025-09-24 | -10.91 |
| 2025-09-23 | -11.44 |
| 2025-09-22 | -12.12 |
| 2025-09-19 | -12.12 |
| 2025-09-18 | -12.40 |
| 2025-09-17 | -11.89 |
| 2025-09-16 | -12.23 |
| 2025-09-15 | -12.50 |
| 2025-09-12 | -11.62 |
| 2025-09-11 | -12.14 |
| 2025-09-10 | -11.56 |
| 2025-09-09 | -12.68 |
| 2025-09-08 | -13.21 |
| 2025-09-05 | -13.25 |
| 2025-09-04 | -12.77 |
| 2025-09-03 | -12.48 |
| 2025-09-02 | -12.52 |
| 2025-08-29 | -13.31 |
| 2025-08-28 | -13.64 |
| 2025-08-27 | -13.32 |
| 2025-08-26 | -13.33 |
| 2025-08-25 | -13.38 |